Healthcare entity

John Sabino

Person

health-it is the sole category represented across all 1 tracked stories. Bakkt is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window.

Last mentioned: Mar 18, 2026

Entity pulse

Recent coverage · John Sabino

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about John Sabino

health-it is the sole category represented across all 1 tracked stories. Bakkt is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 6 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention John Sabino, all published on March 18, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering John Sabino. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. PDUFA Date

    Target date for FDA decision on INO-3107 accelerated approval.

  2. Platform Modernization

    LivePerson expects to complete its multiyear platform modernization.

  3. BLA Acceptance

    FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.

  4. Inovio Cash Position

    Company ends the year with $94.1 million in cash.

Stories mentioning John Sabino 1

Health IT Neutral

Inovio Faces FDA Hurdle for INO-3107 as LivePerson Scales Enterprise AI

Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.

3 sources

Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)

John Sabino is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.